Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AMO959 · BY1298, BY101298

Small molecule · developed by Novartis Pharmaceuticals

Phase 1/2 Most advanced trial
NVS Developer

What is AMO959?

AMO959 (also BY1298, BY101298) is an agent described as a DNA damage response inhibitor. It is being studied in PSMA-positive metastatic castration-resistant prostate cancer in patients who previously received one androgen receptor pathway inhibitor and are candidates for taxane-based chemotherapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BY1298, BY101298
Drug type
Small molecule
Pathways
DNA damage response
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind AMO959

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.